{"id":"oxytrol","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Application site pruritus","drugRate":"16.8%","severity":"common"},{"effect":"Application site erythema","drugRate":"14.0%","severity":"common"},{"effect":"Dry mouth","drugRate":"9.6%","severity":"common"},{"effect":"Application site vesicles","drugRate":"3.2%","severity":"mild"},{"effect":"Diarrhea","drugRate":"3.2%","severity":"mild"},{"effect":"Dysuria","drugRate":"2.4%","severity":"mild"},{"effect":"Application site rash","drugRate":"3.3%","severity":"mild"},{"effect":"Application site macules","drugRate":"2.5%","severity":"mild"},{"effect":"Abnormal vision","drugRate":"2.5%","severity":"mild"},{"effect":"Constipation","drugRate":"3.3%","severity":"mild"},{"effect":"Severe application site reactions","drugRate":"6.4%","severity":"serious"},{"effect":"Memory impairment","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Somnolence","drugRate":"reported","severity":"unknown"},{"effect":"Confusion","drugRate":"reported","severity":"unknown"},{"effect":"Delirium","drugRate":"reported","severity":"unknown"},{"effect":"Hallucinations","drugRate":"reported","severity":"unknown"}],"contraindications":["Angle-closure glaucoma","Atony of colon","Benign prostatic hyperplasia","Bladder outflow obstruction","Chronic heart failure","Conduction disorder of the heart","Disease of liver","Disorder of coronary artery","Drowsy","Gastric retention","Gastroesophageal reflux disease","Gastrointestinal hypomotility","Gastrointestinal obstruction","Hiatal hernia","Hypertensive disorder","Hyperthyroidism","Kidney disease","Myasthenia gravis","Paralytic ileus","Retention of urine","Severe chronic ulcerative colitis","Sinus tachycardia","Toxic megacolon","Ulcerative colitis"]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T18:40:05.197603","offLabel":[],"timeline":[],"_dailymed":{"setId":"20dee37f-1412-44ed-9e8b-f4379ce23eb0","title":"OXYTROL (OXYBUTYNIN) PATCH [ALLERGAN, INC.]"},"ecosystem":[],"mechanism":{"target":"Cytochrome P450 2C19, 5-hydroxytryptamine receptor 2B, D(3) dopamine receptor","modality":"Small Molecule"},"_scrapedAt":"2026-03-27T23:59:27.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Bladder muscle dysfunction - overactive","diseaseId":"bladder-muscle-dysfunction---overactive","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hyperhidrosis of palms","diseaseId":"hyperhidrosis-of-palms","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Increased Urinary Frequency","diseaseId":"increased-urinary-frequency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neurogenic bladder","diseaseId":"neurogenic-bladder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urge incontinence of urine","diseaseId":"urge-incontinence-of-urine","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urgent desire to urinate","diseaseId":"urgent-desire-to-urinate","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","pubmed(17)","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT06993662","phase":"PHASE1","title":"The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rakitzi, Stavroula","startDate":"2025-06-02","conditions":"Anxiety, Depression, Obsessive-compulsive Disorder","enrollment":107},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT07391878","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.","status":"NOT_YET_RECRUITING","sponsor":"Trigone Pharma Ltd.","startDate":"2026-02-15","conditions":"Overactive Bladder (OAB)","enrollment":60},{"nctId":"NCT03952299","phase":"PHASE3","title":"Oxybutynin for Post-surgical Bladder Pain and Urgency","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2021-09-01","conditions":"Overactive Bladder Syndrome, Neuropathic Bladder","enrollment":100},{"nctId":"NCT07259148","phase":"NA","title":"Behavioral Interventions Versus Pelvic Floor Muscle Therapy as Adjuncts to Anticholinergic Pharmacotherapy for Urgency Urinary Incontinence: A Non-Inferiority Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emilio José Dávila Álvarez","startDate":"2025-11-22","conditions":"Urgency Urinary Incontinence","enrollment":80},{"nctId":"NCT02483793","phase":"NA","title":"Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2015-07","conditions":"Disorder of Urinary Stent","enrollment":""},{"nctId":"NCT03919955","phase":"PHASE2","title":"A Novel Pharmacological Therapy for Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-09-03","conditions":"Sleep Apnea","enrollment":117},{"nctId":"NCT05944965","phase":"PHASE1, PHASE2","title":"Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-12-01","conditions":"OSA","enrollment":27},{"nctId":"NCT07280468","phase":"PHASE4","title":"Endotype DIrected Treatment for OSA in Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Arizona","startDate":"2026-02-01","conditions":"Obstructive Sleep Apnea (OSA), Down Syndrome","enrollment":200},{"nctId":"NCT01855256","phase":"PHASE3","title":"Treatment of Hyperhidrosis With Oxybutynin","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2013-06","conditions":"Hyperhidrosis","enrollment":62},{"nctId":"NCT06295562","phase":"PHASE4","title":"Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2024-11-05","conditions":"Obstructive Sleep Apnea of Adult","enrollment":45},{"nctId":"NCT06110975","phase":"NA","title":"Deprescribing dRrugs for Overactive Bladder in General Practice (DROP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anne Estrup Olesen","startDate":"2023-12-01","conditions":"Overactive Bladder, Deprescribing, PIMS","enrollment":72},{"nctId":"NCT07030803","phase":"NA","title":"Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine vs. Transcutaneous Neurostimulation","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-11-05","conditions":"Overactive Bladder (OAB), Transcutaneous Neurostimulation, Posterior Tibial Nerve Stimulation","enrollment":124},{"nctId":"NCT07062133","phase":"NA","title":"Effectiveness of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction in Pediatric Tethered Cord Syndrome Post-Surgery","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Institute of Acupuncture, Moxibustion and Meridian","startDate":"2025-11-01","conditions":"Postoperative Neurogenic Lower Urinary Tract Dysfunction Secondary to Tethered Cord Syndrome","enrollment":50},{"nctId":"NCT04115878","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea In Children With Down Syndrome","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2020-10-21","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":22},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":"Urinary Bladder, Overactive","enrollment":220},{"nctId":"NCT05100017","phase":"NA","title":"Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2021-09-30","conditions":"Kidney Calculi, Kidney Diseases, Nephrolithiasis","enrollment":126},{"nctId":"NCT07081906","phase":"NA","title":"Transdermal Versus Oral Oxybutynin in Pediatric OAB","status":"COMPLETED","sponsor":"Dr. Lutfi Kirdar Kartal Training and Research Hospital","startDate":"2019-02-15","conditions":"Overactive Bladder (OAB), Drug Delivery Systems, Anticholinergic Side Effects","enrollment":90},{"nctId":"NCT07046156","phase":"","title":"Treatment of Overactive Bladder With Anticholinergic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital","startDate":"2022-09-01","conditions":"Overactive Bladder","enrollment":120},{"nctId":"NCT07027020","phase":"PHASE3","title":"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09","conditions":"Spina Bifida","enrollment":60},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT04600336","phase":"PHASE2","title":"Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-28","conditions":"Prostate Carcinoma","enrollment":88},{"nctId":"NCT05658874","phase":"PHASE3","title":"A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jocelyn Fitzgerald","startDate":"2022-12-01","conditions":"Interstitial Cystitis","enrollment":26},{"nctId":"NCT06106529","phase":"PHASE3","title":"REDucing Hot FLASHes in Women Using Endocrine Therapy.","status":"RECRUITING","sponsor":"Reinier de Graaf Groep","startDate":"2024-10-03","conditions":"Breast Cancer, Hot Flash Due to Medication","enrollment":260},{"nctId":"NCT00293839","phase":"PHASE3","title":"Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"","conditions":"Urinary Incontinence","enrollment":790},{"nctId":"NCT06737016","phase":"PHASE3","title":"Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-11-01","conditions":"Posterior Urethral Valve","enrollment":50},{"nctId":"NCT00629642","phase":"PHASE4","title":"Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-03-14","conditions":"Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases","enrollment":249},{"nctId":"NCT03602508","phase":"","title":"Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-20","conditions":"Overactive Bladder (OAB)","enrollment":5589},{"nctId":"NCT02386072","phase":"","title":"A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Scientific & Medical Affairs, Inc.","startDate":"2015-01-05","conditions":"Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases","enrollment":1524},{"nctId":"NCT01192568","phase":"PHASE4","title":"Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2011-05-17","conditions":"Overactive Detrusor, Neurogenic Bladder","enrollment":52},{"nctId":"NCT05933603","phase":"PHASE2","title":"Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-09-29","conditions":"Obstructive Sleep Apnea, Down Syndrome","enrollment":36},{"nctId":"NCT05102396","phase":"PHASE2","title":"Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect?","status":"RECRUITING","sponsor":"Samantha Rodrigues Camargo Neves de Moura","startDate":"2022-09-26","conditions":"Hyperhidrosis, Oxybutynin, Sweat Gland Diseases","enrollment":17},{"nctId":"NCT00649129","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT00649272","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride Extended-Release Tablets 15 mg and Ditropan XL® Tablets 15 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2006-01","conditions":"Healthy","enrollment":80},{"nctId":"NCT00648843","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":28},{"nctId":"NCT00650481","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-12","conditions":"Healthy","enrollment":60},{"nctId":"NCT00649259","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-10","conditions":"Healthy","enrollment":39},{"nctId":"NCT00649727","phase":"PHASE1","title":"Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT06181591","phase":"PHASE2","title":"A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2024-04-01","conditions":"Overactive Bladder","enrollment":44},{"nctId":"NCT06162065","phase":"PHASE1","title":"Effectiveness of Oral Boldo in Women With Overactive Bladder","status":"UNKNOWN","sponsor":"Universidad de Valparaiso","startDate":"2023-11-01","conditions":"Urinary Bladder, Overactive","enrollment":10},{"nctId":"NCT05550246","phase":"PHASE1, PHASE2","title":"Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2022-05-05","conditions":"Obstructive Sleep Apnea","enrollment":22},{"nctId":"NCT01370811","phase":"PHASE2","title":"A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Orient Pharma Co., Ltd.","startDate":"2011-08","conditions":"Sialorrhoea","enrollment":24},{"nctId":"NCT05637671","phase":"PHASE3","title":"Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-02-10","conditions":"Vasomotor Symptoms","enrollment":146},{"nctId":"NCT04580394","phase":"PHASE2","title":"Crossover Trial of AD109 in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Apnimed","startDate":"2020-10-27","conditions":"Obstructive Sleep Apnea","enrollment":60},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":"Cystitis","enrollment":81},{"nctId":"NCT04090190","phase":"PHASE4","title":"Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2019-10-30","conditions":"Urinary Incontinence, Urgency Urinary","enrollment":20},{"nctId":"NCT03205605","phase":"EARLY_PHASE1","title":"Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2018-01-02","conditions":"Heat Effect","enrollment":13},{"nctId":"NCT00816972","phase":"PHASE2","title":"Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Post-nasal Drip, Seasonal Allergic Rhinitis, Rhinorrhea","enrollment":540},{"nctId":"NCT04909255","phase":"PHASE4","title":"Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2021-03-23","conditions":"Sjogren's Syndrome, Overactive Bladder Syndrome","enrollment":50},{"nctId":"NCT01557244","phase":"PHASE3","title":"A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-07-02","conditions":"Urinary Bladder, Neurogenic","enrollment":181},{"nctId":"NCT00411437","phase":"PHASE4","title":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Memory, Cognition","enrollment":220},{"nctId":"NCT04534491","phase":"PHASE3","title":"Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-05-25","conditions":"Overactive Bladder","enrollment":855},{"nctId":"NCT04526353","phase":"PHASE2","title":"Early Oxybutinin Treatment for Boys With Posterior Urethral Valves","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2020-09-10","conditions":"Male Urogenital Diseases","enrollment":50},{"nctId":"NCT03572231","phase":"","title":"A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China","status":"COMPLETED","sponsor":"Astellas Pharma Singapore Pte. Ltd.","startDate":"2018-07-19","conditions":"Overactive Bladder (OAB)","enrollment":805},{"nctId":"NCT02240459","phase":"PHASE2","title":"A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2016-08","conditions":"Overactive Bladder, Mild Cognitive Impairment","enrollment":47},{"nctId":"NCT02961790","phase":"PHASE3","title":"Oxybutynin Chloride in Managing Hot Flashes","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2016-12-09","conditions":"Breast Carcinoma, Ductal Breast Carcinoma In Situ, Hot Flashes","enrollment":150},{"nctId":"NCT03187795","phase":"PHASE2","title":"Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury","status":"UNKNOWN","sponsor":"Kessler Foundation","startDate":"2019-04-03","conditions":"Spinal Cord Injuries, Urinary Bladder, Neurogenic","enrollment":62},{"nctId":"NCT02327936","phase":"PHASE3","title":"Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children","status":"COMPLETED","sponsor":"Stéphane Bolduc","startDate":"2014-12","conditions":"Overactive Bladder","enrollment":62},{"nctId":"NCT01829425","phase":"NA","title":"Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2013-04-22","conditions":"Urinary Incontinence, Urge","enrollment":165},{"nctId":"NCT03829839","phase":"PHASE1","title":"Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity","status":"COMPLETED","sponsor":"University Hospital, Bonn","startDate":"2016-03-03","conditions":"Oxytocin, Lorazepam, Anti-Anxiety Agents, Physiological Effects of Drugs","enrollment":120},{"nctId":"NCT03050827","phase":"PHASE3","title":"Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2014-05-01","conditions":"Diabetic; Neuropathic, Polyneuropathy (Manifestation)","enrollment":51},{"nctId":"NCT02908529","phase":"PHASE1, PHASE2","title":"Atomoxetine and Oxybutynin in Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-09","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":22},{"nctId":"NCT02522936","phase":"PHASE4","title":"Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2018-08-01","conditions":"Overactive Bladder, Xerostomia, Compliance","enrollment":""},{"nctId":"NCT02633371","phase":"NA","title":"A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-02","conditions":"Hyperhidrosis","enrollment":10},{"nctId":"NCT02070042","phase":"NA","title":"Oxybutynin and Omega-3 for OAB (Overactive Bladder)","status":"TERMINATED","sponsor":"TriHealth Inc.","startDate":"2014-02","conditions":"Overactive Bladder","enrollment":31},{"nctId":"NCT02176642","phase":"PHASE4","title":"Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.","status":"TERMINATED","sponsor":"Duke University","startDate":"2014-08","conditions":"Urinary Urge Incontinence","enrollment":55},{"nctId":"NCT00547378","phase":"PHASE4","title":"InSite for Over Active Bladder","status":"COMPLETED","sponsor":"MedtronicNeuro","startDate":"2007-10","conditions":"Urinary Incontinence, Urgency-frequency, Overactive Bladder","enrollment":571},{"nctId":"NCT01824420","phase":"PHASE4","title":"Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2013-03","conditions":"Overactive Bladder","enrollment":129},{"nctId":"NCT02973659","phase":"NA","title":"The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-05","conditions":"Hyperhidrosis","enrollment":61},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT02099695","phase":"PHASE3","title":"Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis","status":"WITHDRAWN","sponsor":"Cristália Produtos Químicos Farmacêuticos Ltda.","startDate":"2015-12","conditions":"Hyperhidrosis","enrollment":""},{"nctId":"NCT02704013","phase":"NA","title":"Urinary Biomarkers in Overactive Bladder in Children","status":"UNKNOWN","sponsor":"Children's Hospital Zagreb","startDate":"2016-04","conditions":"Overactive Bladder","enrollment":50},{"nctId":"NCT01178827","phase":"PHASE4","title":"Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Overactive Bladder","enrollment":20},{"nctId":"NCT02538302","phase":"PHASE3","title":"Minirin Versus Oxybutynin for Nocturnal Enuresis in Children","status":"COMPLETED","sponsor":"Hormozgan University of Medical Sciences","startDate":"2013-07","conditions":"Nocturnal Enuresis","enrollment":66},{"nctId":"NCT00501267","phase":"PHASE1","title":"A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Overactive Bladder","enrollment":24},{"nctId":"NCT00892450","phase":"NA","title":"Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2009-05","conditions":"Parkinson's Disease, Overactive Bladder","enrollment":12},{"nctId":"NCT00909181","phase":"PHASE3","title":"Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence","status":"COMPLETED","sponsor":"Antares Pharma Inc.","startDate":"2009-03","conditions":"Urge Urinary Incontinence, Urinary Frequency","enrollment":626},{"nctId":"NCT01187498","phase":"PHASE3","title":"Behavioral Treatment of Overactive Bladder in Men","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2005-01","conditions":"Overactive Bladder","enrollment":143},{"nctId":"NCT00223821","phase":"NA","title":"Enhancing Conservative Treatment for Urge Incontinence","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2003-09","conditions":"Urinary Incontinence","enrollment":166},{"nctId":"NCT01796548","phase":"PHASE4","title":"Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity","status":"TERMINATED","sponsor":"Janssen-Cilag Ltd.,Thailand","startDate":"2008-12","conditions":"Detrusor Function, Overactive","enrollment":17},{"nctId":"NCT00613327","phase":"PHASE4","title":"An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-09","conditions":"Urinary Bladder, Overactive","enrollment":345},{"nctId":"NCT01956591","phase":"","title":"Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2007-09","conditions":"Hyperhidrosis","enrollment":1100},{"nctId":"NCT01899794","phase":"PHASE4","title":"Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.","status":"COMPLETED","sponsor":"Jewish General Hospital","startDate":"2007-10","conditions":"Urinary Incontinence Mixed (Stress and Urge)","enrollment":66},{"nctId":"NCT01148186","phase":"PHASE4","title":"An Intervention Study to Reduce the Use and Impact of Potentially Inappropriate Medications Among Older Adults","status":"TERMINATED","sponsor":"Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal","startDate":"2010-06","conditions":"Polypharmacy, Incontinence, Insomnia","enrollment":300},{"nctId":"NCT00800462","phase":"PHASE4","title":"Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Toronto Rehabilitation Institute","startDate":"2008-03","conditions":"Spinal Cord Injury, Neurogenic Detrusor Overactivity","enrollment":23},{"nctId":"NCT00990886","phase":"PHASE2","title":"The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2004-04","conditions":"Menopause, Hot Flashes","enrollment":148},{"nctId":"NCT01716624","phase":"PHASE3","title":"Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2011-05","conditions":"Neurogenic Bladder","enrollment":20},{"nctId":"NCT01126424","phase":"PHASE4","title":"A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-04","conditions":"Cognition","enrollment":26},{"nctId":"NCT00926926","phase":"PHASE1","title":"Effects of Oxybutynin Topical Gel on Gastric Emptying","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2009-06","conditions":"Healthy","enrollment":23},{"nctId":"NCT00224016","phase":"PHASE4","title":"Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-12","conditions":"Detrusor Hyperreflexia","enrollment":57},{"nctId":"NCT00224146","phase":"PHASE4","title":"Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2004-05","conditions":"Overactive Bladder, Urinary Incontinence, Quality of Life","enrollment":2878},{"nctId":"NCT01477736","phase":"NA","title":"A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Centro de Reabilitação e Readaptação Dr. Henrique Santillo","startDate":"2009-01","conditions":"Spinal Cord Injury","enrollment":68},{"nctId":"NCT01450332","phase":"NA","title":"Safety and Efficacy of the Knee-T-nol Anterior Cruciate Ligament (ACL) Prosthesis","status":"UNKNOWN","sponsor":"Tavor Ltd.","startDate":"2011-03","conditions":"Anterior Cruciate Ligament Rupture","enrollment":20},{"nctId":"NCT00752141","phase":"PHASE1","title":"Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2008-09","conditions":"Healthy Volunteers","enrollment":153},{"nctId":"NCT01310712","phase":"PHASE4","title":"Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2010-12","conditions":"Hyperhidrosis","enrollment":50},{"nctId":"NCT01423838","phase":"PHASE4","title":"Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder","status":"UNKNOWN","sponsor":"Adana Numune Training and Research Hospital","startDate":"2011-09","conditions":"Overactive Bladder","enrollment":500},{"nctId":"NCT00338624","phase":"PHASE3","title":"An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"2004-05","conditions":"Urination Disorders","enrollment":420},{"nctId":"NCT00269750","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence.","status":"COMPLETED","sponsor":"Alza Corporation, DE, USA","startDate":"1996-07","conditions":"Urge Incontinence","enrollment":100}],"_emaApprovals":[],"_faersSignals":[{"count":2402,"reaction":"DRUG INEFFECTIVE"},{"count":894,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":741,"reaction":"PRODUCT ADHESION ISSUE"},{"count":580,"reaction":"APPLICATION SITE PRURITUS"},{"count":561,"reaction":"DRUG EFFECT DECREASED"},{"count":526,"reaction":"PRURITUS"},{"count":436,"reaction":"OFF LABEL USE"},{"count":398,"reaction":"ERYTHEMA"},{"count":383,"reaction":"PRODUCT QUALITY ISSUE"},{"count":365,"reaction":"RASH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20171024","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20030226","type":"ORIG","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20150710","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20140516","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20240529","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20130710","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20130529","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20121010","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20130703","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20110131","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20171024","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20140718","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20130315","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20121010","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20060705","type":"SUPPL","sponsor":"ALLERGAN","applicationNumber":"NDA021351"},{"date":"20130125","type":"ORIG","sponsor":"ABBVIE","applicationNumber":"NDA202211"},{"date":"20160303","type":"SUPPL","sponsor":"ABBVIE","applicationNumber":"NDA202211"},{"date":"20130816","type":"SUPPL","sponsor":"ABBVIE","applicationNumber":"NDA202211"},{"date":"20140515","type":"SUPPL","sponsor":"ABBVIE","applicationNumber":"NDA202211"},{"date":"20130820","type":"SUPPL","sponsor":"ABBVIE","applicationNumber":"NDA202211"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":17,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug 1","pmid":"40750810","title":"Electrochemical investigation of oxytrol in fizzy drinks and juices via graphene and polymer printed PVC by ANOVA and design expert.","journal":"Scientific reports"},{"date":"2024 Jan","pmid":"37778479","title":"Analyzing Access and Costs of Oral Medications for Overactive Bladder: Uncovering Disparities.","journal":"Urology"},{"date":"2023 Mar 20","pmid":"36897601","title":"Drugs for overactive bladder.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2006","pmid":"30000728","title":"Oxybutinyn.","journal":""},{"date":"2014 Apr","pmid":"25786724","title":"Bioavailability, bioequivalence, and in vitro-in vivo correlation of oxybutynin transdermal patch in rabbits.","journal":"Drug delivery and translational research"}],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Oxytrol","genericName":"Oxytrol","companyName":"Jewish General Hospital","companyId":"jewish-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}